Cognitive Level Enhancement through Vision Exams and Refraction (CLEVER): study protocol for a randomised controlled trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marmamula Srinivas, Alladi Suvarna, Umapathy Keerthana, Chan Ving Fai, MacKenzie Graeme, Lohfeld Lynne, Mettla Asha Latha, Rayasam Sridevi, Gothwal Vijaya K, Narayanan Raja, Pyda Giridhar, Chadalavada Harithaa P, Thomas Priya, Sigwadhi Lovemore Nyasha, Azuara-Blanco Augusto, McDowell Cliona, McMullan Susan, Murphy Lynn, Clarke Mike, Ehrlich Joshua R, Sweenor Bonnielin, O'Neill Ciaran, Komaravolu Shashidhar, Maulik Pallab K, Murthy G V S, Kumar Keshav, Nyshadham Anant, Adhvaryu Achyuta, McCabe Christopher, Bloom David E, Lee Jinkook, Lin Frank, Coghlan Seán, Khanna Rohit C, Congdon Nathan
Аннотация
METHODS: Cognitive Level Enhancement through Vision Exams and Refraction (CLEVER) is a single-centre, open-label, parallel-group, individually-randomised trial. Participants (760 total, 380 in each arm) aged ≥ 60 years with correctable vision impairment at distance and/or near (presenting visual acuity < 6/18 in the better-seeing eye and improving to > = 6/18 with spectacles and/or presenting near vision worse than N6 at 40 cm and improving to N6 with spectacles), normal hearing (able to repeat at least three out of six words whispered from a 50 cm distance in the better ear) and normal cognition (Hindi Mini-mental Status Examination score > 18/31) will be enrolled. After a comprehensive eye examination, intervention group participants will receive distance, near, or bifocal spectacles, while controls will receive a prescription and spectacles at the end of the trial. The primary outcome will be the three-year change in Longitudinal Aging Study in India-Diagnostic Assessment of Dementia (LASI DAD) global cognitive factor score, with and without adjustment for baseline score, age, gender, education and other potential confounders.
CONCLUSION: CLEVER is designed to assess the effectiveness of spectacles as a low-cost intervention to prevent or delay cognitive decline.
TRIAL REGISTRATION: This trial is registered with ClinicalTrials.gov, number NCT05458323, February 15, 2023.